GRAIL is a life sciences company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company has secured over $1B in venture funding led by ARCH Venture Partners and including Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners. If you’re ready to join a mission with meaning, bring your passion to GRAIL. Together we will make history in the fight against cancer.

GRAIL is a life sciences company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company has secured over $1B in venture funding led by ARCH Venture Partners and including Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners. If you’re ready to join a mission with meaning, bring your passion to GRAIL. Together we will make history in the fight against cancer.

Allelica’s PREDICT module is a resource for clinical laboratories and healthcare providers to generate personalized PRS reports for common diseases. The end-to-end solution starts with patient genotype data generated from microarray or lcWGS technology. Users can then choose from a range of diseases to report on, including coronary artery disease, breast cancer, and Alzheimer’s disease. In just a few hours, the platform applies Allelica’s predictive analytics to calculate individual genetic risk scores for the diseases of interest. The technology accounts for a patient’s ancestry by comparing the risk scores to a distribution matched to the individual’s ancestry. The resulting report communicates the individual’s genetic risk of disease in a concise and comprehensible document.

Allelica has created a secure and trusted platform for Polygenic Risk Score analysis and reporting to equip health systems and clinical laboratories with cutting-edge tools to reduce the impact of common disease through genomic medicine. 

All processes performed on the Allelica platform are fully HIPAA and GDPR-compliant. ISO 13485 and ISO 9001 certifications guarantee that Allelica applies medical device quality management processes every step of the way.

Allelica is working with leading health systems and genetics laboratories in the United States and across Europe to advance disease prevention through widened application of PRS in healthcare.